lebrikizumab
Sign in to saveAlso known as TNX-650
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection.
In the Vinony graph
Vinony's link graph records 474 inbound references to lebrikizumab, and connects out to immunosuppressive drug, humanized antibody and monoclonal antibody.
Vinony files it under Anti-interleukin monoclonal antibodies, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Vinony links it to 6 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- monoclonal antibody
Sources (1)
via Wikidata · CC0
~4 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Mechanism of action
- History
- Society and culture
- Legal status
- Brand names
- Research
- References
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection.
The most common side effects include injection site reactions, dry eye and conjunctivitis, including allergic conjunctivitis.
Excerpted from Wikipedia’s “lebrikizumab” article, available under the CC BY-SA 4.0 licence.